Need an investment idea? Check out Popular Stocks and S2O Stock Screener.

Market Price

86.00 

-0.27 -0.3%

as of Jan 22 '19

52 Week Range:

58.59 106.67


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for hematological cancers. The company has agreement with BeiGene, Ltd; Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; Vividion Therapeutics, Inc.; Jounce Therapeutics, Inc.; Prothena Corporation plc; Zymeworks Inc.; and Evotec AG, as well as strategic collaboration with Skyhawk Therapeutics, Inc. and Dragonfly Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Equity (BVPS) 3.53
3.81
4.78
6.36
6.41
6.78
7.19
7.21
6.83
7.25
12.97
growth rate 7.9% 25.5% 33.1% 0.8% 5.8% 6.1% 0.3% -5.3% 6.2% 78.9%
Earnings BIT 516.97
-1,370.00
975.70
1,010.00
1,420.00
1,680.00
1,670.00
2,696.90
2,639.00
3,504.00
5,480.00
growth rate -100.0% 100.0% 3.5% 40.6% 18.3% -0.6% 61.5% -2.2% 32.8% 56.4%
Avg.PE 88.50
-17.60
33.56
31.55
23.75
23.75
50.25
50.85
52.81
48.66
27.57
growth rate -100.0% 100.0% -6.0% -24.7% 0.0% 111.6% 1.2% 3.9% -7.9% -43.3%
ROA 7.14
-38.07
15.80
11.31
13.06
13.40
11.55
13.02
7.22
7.25
10.10
growth rate -100.0% 100.0% -28.4% 15.5% 2.6% -13.8% 12.7% -44.6% 0.4% 39.3%
ROE 9.40
-48.42
19.70
16.97
22.93
25.99
25.70
33.02
25.75
31.94
43.49
growth rate -100.0% 100.0% -13.9% 35.1% 13.3% -1.1% 28.5% -22.0% 24.0% 36.2%
ROIC 5.74
-50.65
18.19
13.25
17.70
18.62
15.81
17.93
11.06
11.53
14.95
growth rate -100.0% 100.0% -27.2% 33.6% 5.2% -15.1% 13.4% -38.3% 4.3% 29.7%
Cur. Ratio 7.12
5.39
7.77
4.06
2.83
3.27
3.88
4.60
4.77
3.67
4.99
growth rate -24.3% 44.2% -47.8% -30.3% 15.6% 18.7% 18.6% 3.7% -23.1% 36.0%
Quick Ratio 6.71
4.81
6.94
3.09
2.33
2.88
3.47
4.13
4.05
3.26
4.70
growth rate -28.3% 44.3% -55.5% -24.6% 23.6% 20.5% 19.0% -1.9% -19.5% 44.2%
Leverage 1.27
1.27
1.23
1.70
1.82
2.06
2.39
2.66
4.57
4.26
4.36
growth rate 0.0% -3.2% 38.2% 7.1% 13.2% 16.0% 11.3% 71.8% -6.8% 2.4%
Balance Sheet Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Acct.Receivable 312.20
438.60
706.40
1,062.28
1,053.70
1,086.70
1,166.70
1,420.90
1,693.00
2,001.00
growth rate 40.5% 61.1% 50.4% -0.8% 3.1% 7.4% 21.8% 19.2% 18.2%
Acct.Payable 853.27
933.10
1,173.30
198.20
240.80
247.00
305.00
growth rate 9.4% 25.7% -83.1% 21.5% 2.6% 23.5%
Cur.Assets 2,841.40
3,844.80
4,343.20
4,353.23
5,533.70
7,550.50
9,712.60
9,400.90
10,868.00
14,892.00
growth rate 35.3% 13.0% 0.2% 27.1% 36.5% 28.6% -3.2% 15.6% 37.0%
Total Assets 4,445.30
5,389.30
10,177.20
10,005.91
11,734.30
13,378.20
17,340.10
26,964.40
28,086.00
30,141.00
growth rate 21.2% 88.8% -1.7% 17.3% 14.0% 29.6% 55.5% 4.2% 7.3%
Cash 1,092.40
1,102.20
1,351.10
1,859.46
2,090.40
3,234.40
4,121.60
4,880.30
6,170.00
7,013.00
growth rate 0.9% 22.6% 37.6% 12.4% 54.7% 27.4% 18.4% 26.4% 13.7%
Inventory 100.20
100.70
260.10
189.57
259.50
340.40
393.10
443.40
498.00
541.00
growth rate 0.5% 158.3% -27.1% 36.9% 31.2% 15.5% 12.8% 12.3% 8.6%
Cur.Liabilities 527.20
494.70
1,070.40
1,539.97
1,690.20
1,945.50
2,112.20
1,968.90
2,959.00
2,987.00
growth rate -6.2% 116.4% 43.9% 9.8% 15.1% 8.6% -6.8% 50.3% 1.0%
Liabilities 953.90
994.70
4,193.20
4,493.18
6,039.80
7,788.30
10,815.30
21,045.40
21,486.00
23,220.00
growth rate 4.3% 321.6% 7.2% 34.4% 29.0% 38.9% 94.6% 2.1% 8.1%
LT Debt 22.64
0.00
0.00
1,247.60
1,275.59
2,771.30
4,196.50
6,265.70
14,162.30
13,789.00
15,838.00
growth rate -100.0% 2.2% 117.3% 51.4% 49.3% 126.0% -2.6% 14.9%
Equity 2,843.94
3,491.30
4,394.60
5,984.00
5,512.73
5,694.50
5,589.90
6,524.80
5,919.00
6,600.00
6,921.00
growth rate 22.8% 25.9% 36.2% -7.9% 3.3% -1.8% 16.7% -9.3% 11.5% 4.9%
Common Shares 864.00
885.00
935.00
939.00
925.00
882.00
861.00
836.00
824.00
803.00
809.00
growth rate 2.4% 5.7% 0.4% -1.5% -4.7% -2.4% -2.9% -1.4% -2.6% 0.8%
Cash Flow Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Capital Expenditures 64.36
0.00
0.00
0.00
132.10
111.50
119.70
150.30
286.00
236.00
279.00
growth rate -100.0% -15.6% 7.4% 25.6% 90.3% -17.5% 18.2%
Cash Dividends 0.00 0.00 0.00 0.00 0.00 0.00
growth rate
Cash From OA 477.50
182.20
909.90
1,181.60
1,776.10
2,018.60
2,225.90
2,806.30
2,785.00
4,165.00
5,246.00
growth rate -61.8% 399.4% 29.9% 50.3% 13.7% 10.3% 26.1% -0.8% 49.6% 26.0%
FCF per Share 0.48
0.12
0.87
1.15
1.51
2.11
2.26
2.82
2.46
4.19
5.59
growth rate -75.0% 625.0% 32.2% 31.3% 39.7% 7.1% 24.8% -12.8% 70.3% 33.4%
Sale Purchase of Stock -2,022.10
-1,567.40
-2,211.80
297.20
252.00
359.00
685.00
growth rate 0.0% 0.0% 100.0% -15.2% 42.5% 90.8%
FCF 413.00
105.00
816.00
1,083.00
1,677.00
1,858.00
2,087.00
2,631.00
2,197.00
3,740.00
4,967.00
growth rate -74.6% 677.1% 32.7% 54.9% 10.8% 12.3% 26.1% -16.5% 70.2% 32.8%
Income Statement Dec '07 Dec '08 Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17
Sales 1,410.00
2,254.80
2,689.90
3,625.70
4,842.10
5,506.70
6,493.90
7,670.40
9,256.00
11,229.00
13,003.00
growth rate 59.9% 19.3% 34.8% 33.6% 13.7% 17.9% 18.1% 20.7% 21.3% 15.8%
Op.Income -1,464.20
841.50
989.60
1,318.10
1,456.20
1,449.90
2,696.90
2,639.00
3,504.00
5,480.00
growth rate 100.0% 17.6% 33.2% 10.5% -0.4% 86.0% -2.2% 32.8% 56.4%
IBT -1,368.80
975.70
1,012.60
1,419.50
1,681.50
1,665.40
2,327.40
2,023.00
2,372.00
4,314.00
growth rate 100.0% 3.8% 40.2% 18.5% -1.0% 39.8% -13.1% 17.3% 81.9%
Net Income -1,533.70
776.70
880.50
1,318.10
1,456.20
1,449.90
1,999.90
1,602.00
1,999.00
2,940.00
growth rate 100.0% 13.4% 49.7% 10.5% -0.4% 37.9% -19.9% 24.8% 47.1%
EPS 0.27
-1.73
0.83
0.94
1.43
1.65
1.68
2.39
1.94
2.49
3.64
growth rate -100.0% 100.0% 13.3% 52.1% 15.4% 1.8% 42.3% -18.8% 28.4% 46.2%
Gross Profit 1,275.61
1,996.50
2,473.60
3,319.20
4,416.20
5,207.60
6,153.50
6,779.40
7,307.00
9,864.00
11,709.00
growth rate 56.5% 23.9% 34.2% 33.1% 17.9% 18.2% 10.2% 7.8% 35.0% 18.7%
R&D 931.20
794.80
1,128.50
1,600.30
1,724.20
2,226.20
1,796.30
2,089.00
3,543.00
3,274.00
growth rate -14.7% 42.0% 41.8% 7.7% 29.1% -19.3% 16.3% 69.6% -7.6%

Quarterly Statements

Item Name Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Earnings BIT 1,134.00
1,581.00
249.00
1,570.00
1,888.00
growth rate 39.4% -84.3% 530.5% 20.3%
Balance Sheet Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Acct.Receivable 1,816.00
2,001.00
1,991.00
2,089.00
2,151.00
growth rate 10.2% -0.5% 4.9% 3.0%
Acct.Payable 263.00
305.00
320.00
294.00
292.00
growth rate 16.0% 4.9% -8.1% -0.7%
Cur.Assets 14,783.00
14,892.00
7,872.00
6,853.00
7,827.00
growth rate 0.7% -47.1% -12.9% 14.2%
Total Assets 31,736.00
30,141.00
34,556.00
33,444.00
34,215.00
growth rate -5.0% 14.7% -3.2% 2.3%
Cash 5,511.00
7,013.00
2,819.00
1,503.00
2,480.00
growth rate 27.3% -59.8% -46.7% 65.0%
Inventory 537.00
541.00
536.00
555.00
510.00
growth rate 0.7% -0.9% 3.5% -8.1%
Cur.Liabilities 4,049.00
2,987.00
3,115.00
4,502.00
3,683.00
growth rate -26.2% 4.3% 44.5% -18.2%
Liabilities 21,886.00
23,220.00
29,384.00
30,014.00
29,355.00
growth rate 6.1% 26.6% 2.1% -2.2%
LT Debt 12,881.00
15,838.00
20,271.00
19,790.00
19,788.00
growth rate 23.0% 28.0% -2.4% 0.0%
Equity 9,850.00
6,921.00
5,172.00
3,430.00
4,860.00
growth rate -29.7% -25.3% -33.7% 41.7%
Common Shares 10.00
10.00
10.00
10.00
10.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Capital Expenditures 44.00
103.00
88.00
80.00
64.00
growth rate 134.1% -14.6% -9.1% -20.0%
Cash Dividends
growth rate
Cash From OA 1,088.00
1,689.00
-325.00
1,229.00
1,924.00
growth rate 55.2% -100.0% 100.0% 56.6%
Sale Purchase of Stock 250.00
48.00
44.00
2.00
growth rate -80.8% -8.3% -95.5%
FCF 1,044.00
1,586.00
-413.00
1,149.00
1,860.00
growth rate 51.9% -100.0% 100.0% 61.9%
Income Statement Sep '17 Dec '17 Mar '18 Jun '18 Sep '18
Sales 3,287.00
3,483.00
3,538.00
3,814.00
3,892.00
growth rate 6.0% 1.6% 7.8% 2.1%
Op.Income 1,134.00
1,581.00
249.00
1,570.00
1,888.00
growth rate 39.4% -84.3% 530.5% 20.3%
IBT 991.00
1,131.00
1,030.00
1,307.00
1,378.00
growth rate 14.1% -8.9% 26.9% 5.4%
Net Income 988.00
-81.00
846.00
1,045.00
1,082.00
growth rate -100.0% 100.0% 23.5% 3.5%
EPS
growth rate
Gross Profit 2,558.00
3,241.00
3,156.00
3,521.00
3,723.00
growth rate 26.7% -2.6% 11.6% 5.7%
R&D 736.00
807.00
1,956.00
1,084.00
1,069.00
growth rate 9.7% 142.4% -44.6% -1.4%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A (86.46)

YOY Growth Grade:

B (67.63)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 22.47 22.40 8.30
EPS / Growth 25.5% 3.84 19.7%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 5.3%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 5.3% 16.8% 16.8%
Future PE 8.30 21.47 21.47
Future EPS 6.46 18.18 18.18
Value Price
MOS %
13.26
-84.6%
96.47
12.2%
96.47
12.2%
MOS Price 6.63 48.23 48.23
IRT 14.58 9.25 9.25

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.